Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. | Available online http content 10 3 209 Review High-mobility group box protein 1 HMGB1 an alarmin mediating the pathogenesis of rheumatic disease David S Pisetsky1 2 Helena Erlandsson-Harris3 and Ulf Andersson4 Division of Rheumatology and Immunology Duke University Medical Center Durham NC USA 2Medical Research Service Durham Veterans Administration Medical Center 3Department of Woman and Child Health Pediatric Rheumatology Research Unit Karolinska Institutet Karolinska University Hospital L8 04 Stockholm S-171 76 Sweden 4Department of Medicine Rheumatology Unit Karolinska Institutet Karolinska University Hospital Q2 09 Stockholm S-171 76 Sweden Corresponding author David S Pisetsky dpiset@ Published 30 June 2008 This article is online at http content 10 3 209 2008 BioMed Central Ltd Arthritis Research Therapy 2008 10 209 doi ar2440 Abstract High-mobility group box protein 1 HMGB1 is a non-histone nuclear protein that has a dual function. Inside the cell HMGB1 binds DNA regulating transcription and determining chromosomal architecture. Outside the cell HMGB1 can serve as an alarmin to activate the innate system and mediate a wide range of physiological and pathological responses. To function as an alarmin HMGB1 translocates from the nucleus of the cell to the extracellular milieu a process that can take place with cell activation as well as cell death. HMGB1 can interact with receptors that include RAGE receptor for advanced glycation endproducts as well as Toll-like receptor-2 TLR-2 and TLR-4 and function in a synergistic fashion with other proinflammatory mediators to induce responses. As shown in studies on patients as well as animal models HMGB1 can play an important role in the pathogenesis of rheumatic disease including rheumatoid arthritis systemic lupus erythematosus and polymyositis among others. New approaches to therapy for these diseases may involve strategies to inhibit HMGB1 release .
